ZYBT
Zhengye Biotechnology Holding Limited
Drug Manufacturers - Specialty & Generic
Market Cap$45M
5Y Perf.-78.7%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
ZYBT vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1712.35T
5Y Perf.+367.5%
ZYBT vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ZYBT | DBVT |
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
| Market Cap | $45M | $1712.35T |
| Revenue (TTM) | $186M | $0.00 |
| Net Income (TTM) | $11M | $-168M |
| Gross Margin | 49.0% | — |
| Operating Margin | 8.8% | — |
| Total Debt | $86M | $22M |
| Cash & Equiv. | $19M | $194M |
ZYBT vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ZYBT
DBVT
| Stock | Jan 25 | May 26 | Return |
|---|---|---|---|
| Zhengye Biotechnolo… (ZYBT) | 100 | 21.3 | -78.7% |
| DBV Technologies S.… (DBVT) | 100 | 467.5 | +367.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ZYBT vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ZYBT leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. DBV Technologies S.A. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
ZYBT
Zhengye Biotechnology Holding Limited
The Income Pick
ZYBT carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 1 yrs, beta 1.87, yield 5.3%
- Rev growth -12.0%, 3Y rev CAGR -4.5%
- -79.9% 10Y total return vs DBVT's -87.0%
Best for: income & stability and growth exposure
DBVT
DBV Technologies S.A.
The Defensive Pick
DBVT is the clearest fit if your priority is sleep-well-at-night and defensive.
- Lower volatility, beta 1.26, Low D/E 12.8%, current ratio 3.67x
- Beta 1.26, current ratio 3.67x
- Beta 1.26 vs ZYBT's 1.87, lower leverage
Best for: sleep-well-at-night and defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ZYBT | -12.0% revenue growth vs DBVT's -100.0% |
| Quality / Margins | ZYBT | 6.1% margin vs DBVT's 0.3% |
| Stability / Safety | DBVT | Beta 1.26 vs ZYBT's 1.87, lower leverage |
| Dividends | ZYBT | 5.3% yield; 1-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | DBVT | +110.4% vs ZYBT's -91.5% |
| Efficiency (ROA) | ZYBT | 2.3% ROA vs DBVT's -89.0% |
ZYBT vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLDBVTLAGGINGZYBT
ZYBTZhengye Biotechnology…
2leads
DBVTDBV Technologies S.A.
3leads
6 Total Categories
CATEGORYLEADERvs ZYBTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
—
—
Valuation MetricsMultiples, price ratios, and targets
DBVT1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ZYBT5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
DBVT5/6
Risk & VolatilityBeta, volatility, and downside exposure
DBVT2/2
Analyst OutlookRatings, price targets, and dividends
ZYBT1/1
Income & Cash Flow (Last 12 Months)
Insufficient data to determine a leader in this category.
Income & Cash Flow (Last 12 Months)
ZYBT and DBVT operate at a comparable scale, with $186M and $0 in trailing revenue.
| Metric | ZYBTZhengye Biotechno… | DBVTDBV Technologies … |
|---|---|---|
| RevenueTrailing 12 months | $186M | $0 |
| EBITDAEarnings before interest/tax | — | -$112M |
| Net IncomeAfter-tax profit | — | -$168M |
| Free Cash FlowCash after capex | — | -$151M |
| Gross MarginGross profit ÷ Revenue | +49.0% | — |
| Operating MarginEBIT ÷ Revenue | +8.8% | — |
| Net MarginNet income ÷ Revenue | +6.1% | — |
| FCF MarginFCF ÷ Revenue | +7.1% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | — | +91.5% |
Insufficient data to determine a leader in this category.
Valuation Metrics
DBVT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | ZYBTZhengye Biotechno… | DBVTDBV Technologies … |
|---|---|---|
| Market CapShares × price | $45M | $1712.35T |
| Enterprise ValueMkt cap + debt − cash | $55M | $1712.35T |
| Trailing P/EPrice ÷ TTM EPS | — | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 9.15x | — |
| Price / SalesMarket cap ÷ Revenue | 1.63x | — |
| Price / BookPrice ÷ Book value/share | 0.86x | 0.66x |
| Price / FCFMarket cap ÷ FCF | 22.89x | — |
DBVT leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
ZYBT leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
ZYBT delivers a 3.3% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $-130 for DBVT. DBVT carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to ZYBT's 0.25x. On the Piotroski fundamental quality scale (0–9), ZYBT scores 5/9 vs DBVT's 4/9, reflecting solid financial health.
| Metric | ZYBTZhengye Biotechno… | DBVTDBV Technologies … |
|---|---|---|
| ROE (TTM)Return on equity | +3.3% | -130.2% |
| ROA (TTM)Return on assets | +2.3% | -89.0% |
| ROICReturn on invested capital | +3.0% | — |
| ROCEReturn on capital employed | +4.7% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 4 |
| Debt / EquityFinancial leverage | 0.25x | 0.13x |
| Net DebtTotal debt minus cash | $68M | -$172M |
| Cash & Equiv.Liquid assets | $19M | $194M |
| Total DebtShort + long-term debt | $86M | $22M |
| Interest CoverageEBIT ÷ Interest expense | 4.07x | -189.82x |
ZYBT leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
DBVT leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DBVT five years ago would be worth $3,090 today (with dividends reinvested), compared to $2,012 for ZYBT. Over the past 12 months, DBVT leads with a +110.4% total return vs ZYBT's -91.5%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs ZYBT's -41.4% — a key indicator of consistent wealth creation.
| Metric | ZYBTZhengye Biotechno… | DBVTDBV Technologies … |
|---|---|---|
| YTD ReturnYear-to-date | -13.5% | +4.9% |
| 1-Year ReturnPast 12 months | -91.5% | +110.4% |
| 3-Year ReturnCumulative with dividends | -79.9% | +19.7% |
| 5-Year ReturnCumulative with dividends | -79.9% | -69.1% |
| 10-Year ReturnCumulative with dividends | -79.9% | -87.0% |
| CAGR (3Y)Annualised 3-year return | -41.4% | +6.2% |
DBVT leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
DBVT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
DBVT is the less volatile stock with a 1.26 beta — it tends to amplify market swings less than ZYBT's 1.87 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DBVT currently trades 76.3% from its 52-week high vs ZYBT's 7.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ZYBTZhengye Biotechno… | DBVTDBV Technologies … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.75x | 1.26x |
| 52-Week HighHighest price in past year | $13.79 | $26.18 |
| 52-Week LowLowest price in past year | $0.68 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +7.1% | +76.3% |
| RSI (14)Momentum oscillator 0–100 | 54.1 | 48.1 |
| Avg Volume (50D)Average daily shares traded | 265K | 252K |
DBVT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
ZYBT leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
ZYBT is the only dividend payer here at 5.27% yield — a key consideration for income-focused portfolios.
| Metric | ZYBTZhengye Biotechno… | DBVTDBV Technologies … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $46.33 |
| # AnalystsCovering analysts | — | 15 |
| Dividend YieldAnnual dividend ÷ price | +5.3% | — |
| Dividend StreakConsecutive years of raises | 1 | 0 |
| Dividend / ShareAnnual DPS | $0.35 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
ZYBT leads this category, winning 1 of 1 comparable metric.
Key Takeaway
DBVT leads in 3 of 6 categories (Valuation Metrics, Total Returns). ZYBT leads in 2 (Profitability & Efficiency, Analyst Outlook).
Best OverallDBV Technologies S.A. (DBVT)Leads 3 of 6 categories
Loading custom metrics...
ZYBT vs DBVT: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is ZYBT or DBVT a better buy right now?
Analysts rate DBV Technologies S.
A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ZYBT or DBVT?
Over the past 5 years, DBV Technologies S.
A. (DBVT) delivered a total return of -69. 1%, compared to -79. 9% for Zhengye Biotechnology Holding Limited (ZYBT). Over 10 years, the gap is even starker: ZYBT returned -79. 9% versus DBVT's -87. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ZYBT or DBVT?
By beta (market sensitivity over 5 years), DBV Technologies S.
A. (DBVT) is the lower-risk stock at 1. 26β versus Zhengye Biotechnology Holding Limited's 1. 75β — meaning ZYBT is approximately 38% more volatile than DBVT relative to the S&P 500. On balance sheet safety, DBV Technologies S. A. (DBVT) carries a lower debt/equity ratio of 13% versus 25% for Zhengye Biotechnology Holding Limited — giving it more financial flexibility in a downturn.
04Which has better profit margins — ZYBT or DBVT?
Zhengye Biotechnology Holding Limited (ZYBT) is the more profitable company, earning 6.
1% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 6. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ZYBT leads at 8. 8% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — ZYBT leads at 49. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — ZYBT or DBVT?
In this comparison, ZYBT (5.
3% yield) pays a dividend. DBVT does not pay a meaningful dividend and should not be held primarily for income.
06Is ZYBT or DBVT better for a retirement portfolio?
For long-horizon retirement investors, Zhengye Biotechnology Holding Limited (ZYBT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (5.
3% yield). Both have compounded well over 10 years (ZYBT: -79. 9%, DBVT: -87. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between ZYBT and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ZYBT is a small-cap income-oriented stock; DBVT is a mega-cap quality compounder stock. ZYBT pays a dividend while DBVT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.